Pros and cons of inhibiting cholesteryl ester transfer protein
- 1 December 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 11 (6) , 589-596
- https://doi.org/10.1097/00041433-200012000-00004
Abstract
Whether or not it is desirable to inhibit cholesteryl ester transfer protein (CETP) has been an important question for over fifteen years since genetic CETP deficiency was found. Recently, some epidemiological studies which have been reported in Japan as well as Western countries help to clarify the atherogenicity of human subjects with mutations or polymorphisms in the CETP gene. In addition, some experimental atherosclerosis studies, in which CETP was inhibited in rabbits with different approaches, have been reported. There was a considerable difference in the atherogenicity of human CETP deficiency and CETP-inhibited rabbits. In this review, we summarize the recent advances in this field as well as discussing the significance of CETP in reverse cholesterol transport, a major protective system against atherosclerosis.Keywords
This publication has 37 references indexed in Scilit:
- A Low Prevalence of Coronary Heart Disease among Subjects with Increased High-Density Lipoprotein Cholesterol Levels, Including Those with Plasma Cholesteryl Ester Transfer Protein DeficiencyPreventive Medicine, 1998
- Genetic Cholesteryl Ester Transfer Protein Deficiency Is Extremely Frequent in the Omagari Area of JapanArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Molecular genetics of plasma cholesteryl ester transfer proteinCurrent Opinion in Lipidology, 1997
- Changes in Plasma Lipoprotein Cholesterol Levels by Antisense Oligodeoxynucleotides against Cholesteryl Ester Transfer Protein in Cholesterol-fed RabbitsPublished by Elsevier ,1996
- Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.Journal of Clinical Investigation, 1996
- Cholesteryl ester transfer protein: friend or foe?Journal of Clinical Investigation, 1996
- Atherosclerotic Disease in Marked HyperalphalipoproteinemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene.Journal of Clinical Investigation, 1995
- Plasma cholesteryl ester transfer protein and high‐density lipoproteins: new insights from molecular genetic studiesJournal of Internal Medicine, 1995
- Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer proteinNature, 1993